395 related articles for article (PubMed ID: 28857485)
1. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
Ma C; Zhang Q; Greten TF
FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
[TBL] [Abstract][Full Text] [Related]
2. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF
Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227
[TBL] [Abstract][Full Text] [Related]
3. Deranged hepatocyte intracellular Ca
Ali ES; Rychkov GY; Barritt GJ
Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.
Michael C; Martínez-Navarro FJ; de Oliveira S
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871465
[TBL] [Abstract][Full Text] [Related]
8. NAFLD-related HCC.
Banini BA; Sanyal AJ
Adv Cancer Res; 2021; 149():143-169. PubMed ID: 33579423
[TBL] [Abstract][Full Text] [Related]
9. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
11. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
12. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
Koo SY; Park EJ; Lee CW
Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease.
Gentric G; Maillet V; Paradis V; Couton D; L'Hermitte A; Panasyuk G; Fromenty B; Celton-Morizur S; Desdouets C
J Clin Invest; 2015 Mar; 125(3):981-92. PubMed ID: 25621497
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
15. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
[TBL] [Abstract][Full Text] [Related]
16. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
Agosti P; Sabbà C; Mazzocca A
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
[TBL] [Abstract][Full Text] [Related]
17. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
18. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
19. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans.
Chen K; Ma J; Jia X; Ai W; Ma Z; Pan Q
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):117-125. PubMed ID: 30528647
[TBL] [Abstract][Full Text] [Related]
20. NAFLD Related-HCC: The Relationship with Metabolic Disorders.
Zhang X
Adv Exp Med Biol; 2018; 1061():55-62. PubMed ID: 29956206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
